Skip to main content
SpringerLink
Log in

Lomefloxacin Clinical Pharmacokinetics

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Lomefloxacin is a quinolone antibiotic with chemical and microbiological properties similar to most commercially available agents of this class. There are differences, however, between lomefloxacin and other quinolones in activity against specific micro-organisms, a situation that is typical of most antibiotic classes.

The pharmacokinetics of lomefloxacin support once- or twice-daily dosage, depending on the pathogen or site of infection. This is a result of its relatively high serum concentrations and long half-life. The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution, lack of significant metabolism (and, therefore, no competitive drug interactions with other metabolised drugs showing a common metabolic pathway), and good oral absorption. Like most fluoroquinolones, lomefloxacin can chelate with heavy metals. However, this interaction can be eliminated by administering lomefloxacin 2h before the cation-containing products. Dosage adjustments are required in patients with renal dysfunction. However, patients with liver disease do not require alterations in lomefloxacin dosage regimens.

The safety profile, lack of significant drug interactions and convenience of administration make lomefloxacin a useful agent in specific clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epilepto-genicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrobial Agents and Chemotherapy 33: 1704–1708, 1989

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DR, Honeybourne D, Andrews JM, Ashby JP, Wise R. Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrobial Agents and Chemotherapy 34: 1017–1019, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bergogne-Bérézin E, Muller-Serieys C, Kafe H. Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration. American Journal of Medicine 92 (Suppl. 4A): 12S–14S, 1992

    Google Scholar 

  • Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31: 1054–1060, 1987

    Article  PubMed  CAS  Google Scholar 

  • Blum RA. Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fiuoroquinolones. American Journal of Medicine 92 (Suppl. 4A): 18S–21S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Blum RA, Schultz RW, Schentag JJ. Pharmacokinetics of lomefloxacin in renally compromised patients. Antimicrobial Agents and Chemotherapy 34: 2364–2368, 1990

    Article  PubMed  CAS  Google Scholar 

  • Chamberland S, Bayer AS, Schollaardt T, Wong SA, Bryan LE. Characterisation of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrobial Agents and Chemotherapy 33: 624–634, 1989

    Article  PubMed  CAS  Google Scholar 

  • Chambers ST, Peddie BA, Robson RA, Begg EJ, Boswell DR. Antimicrobial effects of lomefloxacin in vitro. Journal of Antimicrobial Chemotherapy 27: 481–489, 1991

    Article  PubMed  CAS  Google Scholar 

  • Chin NX, Novelli A, Neu HC. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrobial Agents and Chemotherapy 32: 656–662, 1988

    Article  PubMed  CAS  Google Scholar 

  • Christ W, Gindler K, Gruene S, Hecker W, Jacobson M, et al. Interactions of quinolones with opioids and fenbufen, a nonsteroidal antiinflamatory drug: involvement of dopaminergic neurotransmission. Reviews of Infectious Diseases 11 (Suppl. 5): S1393–S1394, 1989

    Google Scholar 

  • Chu DTW, Fernandes PB. Structure-activity relationships of the fiuoroquinolones. Antimicrobial Agents and Chemotherapy 33: 131–135, 1989

    Article  PubMed  CAS  Google Scholar 

  • Chu DTW, Fernandes PB, Claiborne AK, Pihuleac E, Nordeen CW, et al. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. Journal of Medicinal Chemistry 28: 1558–1564, 1985

    Article  PubMed  CAS  Google Scholar 

  • Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurray LM, et al. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrobial Agents and Chemotherapy 32: 1187–1191, 1988

    Article  PubMed  CAS  Google Scholar 

  • Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence. Antimicrobial Agents and Chemotherapy 34: 681–684, 1990

    Article  PubMed  CAS  Google Scholar 

  • Cowling P, Rogers S, McMullen CM, White LO, Lovering AM, et al. The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400mg. Journal of Antimicrobial Chemotherapy 28: 101–107, 1991

    Article  PubMed  CAS  Google Scholar 

  • Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Disease (Suppl. 74): 63–70, 1991

    Google Scholar 

  • Crome P, Morrison PJ. Pharmacokinetics of a single dose of lomefloxacin in healthy elderly volunteers. Drug Investigation 3: 183–187, 1991

    Article  Google Scholar 

  • Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. Journal of Antimicrobial Chemotherapy 13 (Suppl. B): 9–23, 1984

    PubMed  CAS  Google Scholar 

  • Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrobial Agents and Chemotherapy 8: 251–261, 1975

    Article  PubMed  CAS  Google Scholar 

  • Cundy KV, Fasching CE, Willard KE, Peterson LR. Uptake of 3H-norfloxacin in methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 28: 491–497, 1991

    Article  PubMed  CAS  Google Scholar 

  • Daikos GL, Lolans VT, Jackson GG. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrobial Agents and Chemotherapy 32: 785–787, 1988

    Article  PubMed  CAS  Google Scholar 

  • Debbia EA, Pesce A. Schito GC. In vitro assessment of the postantibiotic effect of lomefloxacin against Gram-positive and Gram-negative pathogens. American Journal of Medicine 92 (Suppl. 4A): 45S–47S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Domagala JM, Hanna LD, Heifetz CL, Hutt MP, Mich TF, et al. New structure-activity relationships of the quinolone antibac-terials using the target enzyme. Development and application of a DNA gyrase assay. Journal of Medicinal Chemistry 29: 394–404, 1986

    Article  PubMed  CAS  Google Scholar 

  • Drusano GL, Johnson DE, Rosen M, Lockatell V, Standiford HC. Pharmacodynamics of the fluoroquinolone antibiotic lomefloxacin. Abstract no. 1916. Program and Abstracts of the Seventeenth International Congress of Chemotherapy, Berlin, June 23–28, 1991b

  • Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas aeruginosa sepsis. Antimicrobial Agents and Chemotherapy 37: 483–490, 1992

    Article  Google Scholar 

  • Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. American Journal of Medicine 91 (Suppl. 6A): 45S–50S, 1991

    Article  PubMed  CAS  Google Scholar 

  • Eagle H, Fleischman R, Musselman AD. Effect of schedule of administration on the therapeutic efficacy of penicillin. Americal Journal of Medicine 9: 280–299, 1950

    Article  CAS  Google Scholar 

  • Fasching CE, Tenover FC, Slama TG, Fisher LM, Sreedharan S, et al. gyrA Mutations in ciprofloxacin-resistant Stapylococcus aureus from Indiana, Minnesota, and Tennessee. Journal of Infectious Diseases 164: 976–979, 1991

    Article  PubMed  CAS  Google Scholar 

  • Fernandes PB, Swanson RN. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies. Drugs in Experimental Clinical Research 14: 375–378, 1988

    CAS  Google Scholar 

  • Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EEC, et al. Ciprofloxacin and the fluoroquinolones: new concepts on the mechanism of action and resistance. American Journal of Medicine 87 (Suppl. 5A): 2S–8S, 1989

    Article  PubMed  CAS  Google Scholar 

  • Foster T, Blouin R. The effect of antacid timing on lomefloxacin bioavailability. Abstract no. 1277. Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, September 17–20, 1989

  • Furet YX, Pechere JC. Usual and unusual antibacterial effects of quinolones. Journal of Antimicrobial Chemotherapy 26 (Suppl. B): 7–15, 1990

    PubMed  CAS  Google Scholar 

  • Griggs DJ, Wise R. A simple isocratic high-pressure liquid Chromatographic assay of quinolones in serum. Journal of Antimicrobial Chemotherapy 24: 437–445, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gros I, Carbon C. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. Antimicrobial Agents and Chemotherapy 34: 150–152, 1990

    Article  PubMed  CAS  Google Scholar 

  • Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of an interaction between lomefloxacin and caffeine in normal volunteers. Antimicrobial Agents and Chemotherapy 35: 660–664, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hirose T, Okezaki E, Kato H, Ito Y, Inoue M, et al. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrobial Agents and Chemotherapy 31: 854–859, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hoffler D, Waetcke K, Koeppe P, Metz R, Sorgel F. Pharmacokinetics of lomefloxacin in normal and impaired renal function. Acta Therapeutica 15: 321–336, 1989

    Google Scholar 

  • Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, et al. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrobial Agents and Chemotherapy 33: 283–290, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hooper WD, Dickinson RG, Eadie MJ. Effect of food on absorption of lomefloxacin. Antimicrobial Agents and Chemotherapy 34: 1797–1799, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hori S, Shimada J, Saito A, Matsuda M, Miyahara T. Comparison of the inhibitory effects of new quinolones on gamma-aminobytyric acid receptor binding in the presence of antiinflammatory drugs. Reviews of Infectious Diseases 11 (Suppl. 5): S1397–S1398, 1988

    Google Scholar 

  • Hunt TL, Adams MA. Pharmacokinetics and safety of lomefloxacin following multiple doses. Diagnostic Microbiology and Infectious Diseases 12: 181–187, 1989

    Article  CAS  Google Scholar 

  • Jaber LA, Bailey EM, Rybak M. Enoxacin: a new fluoroquinolone. Clinical Pharmacy 8: 97–107, 1989

    PubMed  CAS  Google Scholar 

  • Kaatz GW, Barriere SL, Schaberg DR, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. Journal of Antimicrobial Chemotherapy 20: 753–758, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. Journal of Infectious Diseases 163: 1080–1086, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kavi J, Stone J, Andrews JM, Ashby JP, Wise R. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. European Journal of Clinical Microbiology and Infectious Disease 8: 168–170, 1989

    Article  CAS  Google Scholar 

  • Koga J, Itch A, Marimba S, Cease S, Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. Journal of Medicinal Chemistry 23: 1358–1363, 1980

    Article  PubMed  CAS  Google Scholar 

  • Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. Journal of Infectious Diseases 161: 41–44, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kovarik JM, de Hond JAPM, Hoepelman IM, Boon T, Verhoef J. Intraprostatic distribution of lomefloxacin following multiple-dose administration. Antimicrobial Agents and Chemotherapy 34: 2398–2401, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kovarik JM, Hoepelman AIM, Smit JM, Sips PA, Rozenberg-Arska M, et al. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic pulmonary disease and acute respiratory tract infections. Antimicrobial Agents and Chemotherapy 36: 2458–2461, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kresken M, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 32: 1285–1288, 1988

    Article  PubMed  CAS  Google Scholar 

  • Krueger JH, Walker GC. groEL and dnaK genes of Escherichia coli are induced by UV irradiation and nalidixic acid in an htpR+-dependent fashion. Proceedings of the National Academy of Science of the United States of America 81: 1499–1503, 1984

    Article  CAS  Google Scholar 

  • Kurkemeyer J, Lima J, Adams M, Hunt T. Lomefloxacin pharmacokinetics: binding to plasma proteins and the effect of food on absorption. Abstract no. 1274. Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, September 17–20, 1989

  • Kuzuya T, Takagi K, Apichartpichean R, Muraoka I, Nadai M, et al. Kinetic interaction between theophylline and a newly developed quinolone NY-198. Journal of Pharmacobio-Dynamics 12: 405–409, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lebel M, Vallee F, Marcotte N, St-Laurent M. Tissue penetration of lomefloxacin in young and elderly healthy volunteers. Abstract no. 84E. Pharmacotherapy 9: 185, 1989

    Google Scholar 

  • Lebel M, Vallee F, St-Laurent M. Influence of lomefloxacin on the pharmacokinetics of theophylline. Antimicrobial Agents and Chemotherapy 34: 1254–1256, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lebrec D, Gaudin C, Benhamou JP. Pharmacokinetics of lomefloxacin in patients with cirrhosis. American Journal of Medicine 92 (Suppl. 4A): 41S–44S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scandinavian Journal of Infectious Disease (Suppl. 74): 179–184, 1991

    Google Scholar 

  • Leigh DA, Harris C, Tait S, Walsh B, Hancock P. Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. Journal of Antimicrobial Chemotherapy 27: 655–662, 1991

    Article  PubMed  CAS  Google Scholar 

  • Leroy A, Fillastre JP, Humbert G. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrobial Agents and Chemotherapy 34: 17–20, 1990

    Article  PubMed  CAS  Google Scholar 

  • Leroy A, Humbert G, Fillastre J-P, Grise P. Penetration of lomefloxacin into human prostatic tissue. American Journal of Medicine 92 (Suppl. 4A): 12S–14S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Mant TGK. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. American Journal of Medicine 92 (Suppl. 4A): 26S–32S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Mayer KH, Ellal JA. Lomefloxacin: microbiological assessment and unique properties. American Journal of Medicine 92 (Suppl. 4A): 58S–62S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Mayersohn M. Special pharmacokinetic considerations in the elderly. In Evans et al. (Eds) Applied pharmacokinetics, 2nd ed., pp. 229–293, Applied Therapeutics, Inc., Washington, 1987

    Google Scholar 

  • Meng X, Nightingale CH, Sweeney KR, Quintiliani R. Loss of bactericidal activity of quinolones (Q) in the presence of postantibiotic effect (PAE) induced by rifampin (R). Abstract no. 539. Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, October 11–14, 1992

  • Metz R, Hoffler D, Waetcke K, Keoppe P, Seibel M, et al. Altered pharmacokinetics of lomefloxacin (LFX) in patients with impaired renal function. Abstract no. 1271. Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, September 17–20, 1989

  • Minguez F, Ramos C, Barrientos S, Loscos A, Prieto J. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones. Chemotherapy 37: 420–425, 1991

    Article  PubMed  CAS  Google Scholar 

  • Molinari G, Bandelloni R, Paglia P, Debbia E, Schito GC. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone. Diagnostic Microbiology and Infectious Diseases 12 (Suppl. 3): 53S–56S, 1989

    Article  CAS  Google Scholar 

  • Morrison PJ, Mant TGK, Norman GT, Robinson J, Kunka RL. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrobial Agents and Chemotherapy 32: 1503–1507, 1988

    Article  PubMed  CAS  Google Scholar 

  • Morse IS. Pharmacokinetics and safety of single oral doses of lomefloxacin. Biopharmaceutics and Drug Disposition 11: 543–551, 1990

    Article  CAS  Google Scholar 

  • Nagata O, Yamada T, Yamaguchi T, Hasegawa H, Okezaki E. Disposition and metabolism of NY-198 V. Metabolism of 14C-NY-198 in rats and dogs. Chemotherapy 36 (Suppl. 2): 174–187, 1988

    CAS  Google Scholar 

  • Neu HC. The crisis in antibiotic resistance. Science 257: 1064–1073, 1992

    Article  PubMed  CAS  Google Scholar 

  • Nilsen OG, Saltvedt E, Walstad RA, Marstein S. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. American Journal of Medicine 92 (Suppl. 4A): 38S–40S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Nix DE, Norman A, Schentag JJ. Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrobial Agents and Chemotherapy 33: 1006–1008, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nix D, Schentag J. Lomefloxacin (L) absorption kinetics when administered with ranitidine (R) and sucralfate (S). Abstract no. 1276. Program and Abstracts of the Twenty-Ninth Inter-science Conference on Antimicrobial Agents and Chemotherapy, Houston, September 17–20, 1989

  • On A, Nightingale CH, Quintiliani R, Sweeney KR, Pasternak HS, et al. Lomefloxacin concentrations in bone after a single oral dose. American Journal of Medicine 92 (Suppl. 41): 155–175, 1992

    Google Scholar 

  • Pascual A, Garcia I, Perea EJ. Fluometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 33: 653–656, 1989

    Article  PubMed  CAS  Google Scholar 

  • Percival A. Impact of chemical structure on quinolone potency, spectrum and side effects. Journal of Antimicrobial Chemotherapy 28 (Suppl. C): 1–8, 1991

    PubMed  CAS  Google Scholar 

  • Perea EJ, Garcia I, Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. American Journal of Medicine 92 (Suppl. 4A): 48S–51S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Piddock LJV, Hall MC, Wise R. Mechanism of action of lomefloxacin. Antimicrobial Agents and Chemotherapy 34: 1088–1093, 1990

    Article  PubMed  CAS  Google Scholar 

  • Pruul H, McDonald PJ. Lomefloxacin-induced modification of the kinetics of growth of Gram-negative bacteria and susceptibility of phagocytic killing by human neutrophils. Journal of Antimicrobial Chemotherapy 25: 91–101, 1990

    Article  PubMed  CAS  Google Scholar 

  • Reeves DS, Bywater MJ, Holt HA, White LO. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. Journal of Antimicrobial Chemotherapy 13: 333–346, 1984

    Article  PubMed  CAS  Google Scholar 

  • Robillard NJ, Scarpa AL. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrobial Agents and Chemotherapy 32: 535–539, 1988

    Article  PubMed  CAS  Google Scholar 

  • Robson RA. The effects of quinolones on xanthine pharmacokinetics. American Journal of Medicine 92 (Suppl. 4A): 22S–25S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Robson RA, Begg EJ, Atkinson HC, Saunders DA, Frampton CM. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. British Journal of Clinical Pharmacology 29: 491–493, 1990

    Article  PubMed  CAS  Google Scholar 

  • Rustige C, Wiedemann B. Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. Antimicrobial Agents and Chemotherapy 34: 1107–1111, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sanders CC, Sanders WE, Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrobial Agents and Chemotherapy 26: 797–801, 1984

    Article  PubMed  CAS  Google Scholar 

  • Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. Journal of Clinical Microbiology 27: 335–336, 1989

    PubMed  CAS  Google Scholar 

  • Schentag JJ, Goss TF. Quinolone pharmacokinetics in the elderly. American Journal of Medicine 92 (Suppl. 4A): 33S–37S, 1992

    Article  PubMed  CAS  Google Scholar 

  • Searle Laboratories. Maxaquin package insert. Skookie, March 1992

    Google Scholar 

  • Shah PM, Muller S, Kipp J, Stille W. In vitro activity of lomefloxacin (NY-198 or SC 47111). Diagnostic Microbiology and Infectious Diseases 12 (Suppl. 3): 97S–101S, 1989

    Article  CAS  Google Scholar 

  • Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proceedings of the National Academy of Science of the United States of America 82: 307–311, 1985

    Article  CAS  Google Scholar 

  • Shibl AM, Tawfik AKF, El-Houfy S, Al-Shammary FJ. Determination of lomefloxacin in biological fluids by high-performance liquid chromatography and a microbiological method. Journal of Clinical Pharmacy and Therapeutics 16: 353–359, 1991

    Article  PubMed  CAS  Google Scholar 

  • Shimada J, Shiba K, Oguma T, Miwa H, Yoshimura Y, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrobial Agents and Chemotherapy 36: 1219–1224, 1992

    Article  PubMed  CAS  Google Scholar 

  • Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 21–29, 1986

    PubMed  CAS  Google Scholar 

  • Sorgel F, Jaehde U, Naber K, Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clinical Pharmacokinetics 16 (Suppl. 1): 5–24, 1989

    Article  PubMed  Google Scholar 

  • Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. International Journal of Clinical Pharmacology Therapy and Toxicology 27: 289–293, 1989

    CAS  Google Scholar 

  • Stein GE. Drug interactions with fluoroquinolones. American Journal of Medicine 91 (Suppl. 6A): 81S–86S, 1991

    Article  PubMed  CAS  Google Scholar 

  • Stevens PJE. Bactericidal effect against Escherichia coli of nalidixic acid and four structurally related compounds. Journal of Antimicrobial Chemotherapy 6: 535–542, 1980

    Article  PubMed  CAS  Google Scholar 

  • Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrobial Agents and Chemotherapy 32: 1508–1510, 1988

    Article  PubMed  CAS  Google Scholar 

  • Stratum CW, Weeks LS. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens. Diagnostic Microbiology and Infectious Diseases 12 (Suppl. 3): 29S–34S, 1989

    Article  Google Scholar 

  • Tsuji A, Sato H, Kume Y, Tamai I, Okezaki E, et al. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrobial Agents and Chemotherapy 32: 190–194, 1988

    Article  PubMed  CAS  Google Scholar 

  • Van der Auwera P, Grenier P, Glupczynski Y, Pierard D. In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin. Journal of Antimicrobial Chemotherapy 23: 209–219, 1989

    Article  PubMed  Google Scholar 

  • Wijnands GJA, Cornel JH, Martea M, Vree TB. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man. Chest 98: 1440–1444, 1990

    Article  PubMed  CAS  Google Scholar 

  • Wise R, Andrews JM, Ashby JP, Matthews RS. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrobial Agents and Chemotherapy 32: 617–622, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 23: 559–564, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wise R, Baldwin DR, Andrews JM, Honeybourne D. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. Journal of Antimicrobial Chemotherapy 28 (Suppl. C): 65–71, 1991

    PubMed  CAS  Google Scholar 

  • Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 28: 581–586, 1985

    Article  PubMed  CAS  Google Scholar 

  • Woodworth J, Fitzsimmons S. Lomefloxacin pharmacokinetics in young and elderly subjects. Abstract no. 1268. Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, September 17–20, 1989

  • Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial Agents and Chemotherapy 34: 1271–1272, 1990

    Article  PubMed  CAS  Google Scholar 

  • Zweerink MM, Edison A. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrobial Agents and Chemotherapy 29: 598–601, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy and Office for Research, Hartford Hospital, Hartford, Connecticut, USA

    Collin D. Freeman, David P. Nicolau, Paul P. Belliveau &  Charles H. Nightingale (Vice-President for Research, Office for Research)

  2. School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA

    Collin D. Freeman, David P. Nicolau, Paul P. Belliveau &  Charles H. Nightingale (Vice-President for Research, Office for Research)

Authors
  1. Collin D. Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Nicolau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul P. Belliveau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles H. Nightingale
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freeman, C.D., Nicolau, D.P., Belliveau, P.P. et al. Lomefloxacin Clinical Pharmacokinetics. Clin. Pharmacokinet. 25, 6–19 (1993). https://doi.org/10.2165/00003088-199325010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325010-00002

Search

Navigation